Literature DB >> 26557893

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.

Kate Young1, Elizabeth Smyth1, Ian Chau2.   

Abstract

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

Entities:  

Keywords:  angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2

Year:  2015        PMID： 26557893      PMCID： PMC4622287          DOI： 10.1177/1756283X15592586

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  22 in total

1.  Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.

Authors:  Ling Peng; Ping Zhan; Yun Zhou; Weijia Fang; Peng Zhao; Yulong Zheng; Nong Xu
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

3.  Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Authors:  Hua-Quan Miao; Kun Hu; Xenia Jimenez; Elizabeth Navarro; Haifan Zhang; Dan Lu; Dale L Ludwig; Paul Balderes; Zhenping Zhu
Journal:  Biochem Biophys Res Commun       Date:  2006-05-02       Impact factor: 3.575

4.  Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

Authors:  Hugo E R Ford; Andrea Marshall; John A Bridgewater; Tobias Janowitz; Fareeda Y Coxon; Jonathan Wadsley; Wasat Mansoor; David Fyfe; Srinivasan Madhusudan; Gary W Middleton; Daniel Swinson; Stephen Falk; Ian Chau; David Cunningham; Paula Kareclas; Natalie Cook; Jane M Blazeby; Janet A Dunn
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

5.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors:  Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

6.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Authors:  Shuichi Hironaka; Shinya Ueda; Hirofumi Yasui; Tomohiro Nishina; Masahiro Tsuda; Takehiko Tsumura; Naotoshi Sugimoto; Hideki Shimodaira; Shinya Tokunaga; Toshikazu Moriwaki; Taito Esaki; Michitaka Nagase; Kazumasa Fujitani; Kensei Yamaguchi; Takashi Ura; Yasuo Hamamoto; Satoshi Morita; Isamu Okamoto; Narikazu Boku; Ichinosuke Hyodo
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

7.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.

Authors:  H S Kim; H J Kim; S Y Kim; T Y Kim; K W Lee; S K Baek; T Y Kim; M H Ryu; B H Nam; D Y Zang
Journal:  Ann Oncol       Date:  2013-08-13       Impact factor: 32.976

Review 10.  VEGFA and tumour angiogenesis.

Authors:  L Claesson-Welsh; M Welsh
Journal:  J Intern Med       Date:  2013-02       Impact factor: 8.989
View more
  5 in total

1.  Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report.

Authors:  Tiago Biachi de Castria; Laura Tang; Marcello Moro Queiroz; Beatriz Mendes Awni; Viktoriya Paroder; Ali Shamseddine; Giovanni Mendonca Bariani; Deborah Mukherji; Charbel F Matar; Gustavo Dos Santos Fernandes; Ashwaq El-Olayan; Fouad Sabatin; Rawad Elias; Ranju Gupta; Yelena Y Janjigian; Ghassan K Abou-Alfa
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

3.  PIWIL1 promotes gastric cancer via a piRNA-independent mechanism.

Authors:  Shuo Shi; Zhen-Zhen Yang; Sanhong Liu; Fan Yang; Haifan Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-26       Impact factor: 11.205

4.  Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Authors:  Anne Steins; Eva A Ebbing; Marcel C M Pistorius; Cynthia Waasdorp; Kausilia K Krishnadath; Jan Paul Medema; Johanna W Wilmink; Ron A A Mathôt; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma.

Authors:  Anne Steins; Remy Klaassen; Igor Jacobs; Matthias C Schabel; Monique G J T B van Lier; Eva A Ebbing; Stefanie J Hectors; Sander W Tas; Chrissta X Maracle; Cornelis J A Punt; Maria Siebes; Jacques J G H M Bergman; Jan Paul Medema; Johanna W Wilmink; Ron A A Mathot; Gustav J Strijkers; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Mol Oncol       Date:  2020-03-03       Impact factor: 6.603
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.